Yasuda M - Search Results

1

Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.

Isonishi S, Saitou M, Saitou M, Yasuda M, Tanaka T. Isonishi S, et al. Among authors: yasuda m. Oncol Rep. 2007 Jul;18(1):195-201. Oncol Rep. 2007. PMID: 17549368

2

Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells.

Isonishi S, Saitou M, Yasuda M, Ochiai K, Tanaka T. Isonishi S, et al. Among authors: yasuda m. Gynecol Oncol. 2003 Aug;90(2):413-20. doi: 10.1016/s0090-8258(03)00316-0. Gynecol Oncol. 2003. PMID: 12893210

3

Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer.

Isonishi S, Hirama M, Saitou M, Yasuda M, Tanaka T. Isonishi S, et al. Among authors: yasuda m. Int J Clin Oncol. 2006 Jun;11(3):236-42. doi: 10.1007/s10147-006-0561-x. Int J Clin Oncol. 2006. PMID: 16850131

4

Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.

Hirama M, Isonishi S, Yasuda M, Ishikawa H. Hirama M, et al. Among authors: yasuda m. Oncol Rep. 2006 Nov;16(5):997-1002. Oncol Rep. 2006. PMID: 17016583

5

Small cell carcinoma of the ovary: clinical and biological study.

Isonishi S, Nishii H, Saitou M, Yasuda M, Kiyokawa T, Fukunaga M, Ishikawa H, Tanaka T. Isonishi S, et al. Among authors: yasuda m. Int J Clin Oncol. 2008 Apr;13(2):161-5. doi: 10.1007/s10147-007-0698-2. Epub 2008 May 8. Int J Clin Oncol. 2008. PMID: 18463962

6

Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer.

Saitou M, Isonishi S, Hamada T, Kiyokawa T, Tachibana T, Ishikawa H, Yasuda M. Saitou M, et al. Among authors: yasuda m. Oncol Rep. 2009 Jan;21(1):199-204. Oncol Rep. 2009. PMID: 19082462

7

Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.

Isonishi S, Niimi S, Sasaki H, Ochiai K, Yasuda M, Tanaka T. Isonishi S, et al. Among authors: yasuda m. Gynecol Oncol. 2004 Jun;93(3):647-52. doi: 10.1016/j.ygyno.2004.03.006. Gynecol Oncol. 2004. PMID: 15196859

8

Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.

Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T. Tanabe H, et al. Among authors: yasuda m. Gynecol Oncol. 2004 Sep;94(3):735-9. doi: 10.1016/j.ygyno.2004.05.055. Gynecol Oncol. 2004. PMID: 15350366

9

Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3.

Ueda K, Yamada K, Urashima M, Ishibashi Y, Shirai M, Nikaido T, Takahashi H, Okamoto A, Saito M, Yasuda M, Ohkawa K, Tanaka T. Ueda K, et al. Among authors: yasuda m. Oncol Rep. 2007 Apr;17(4):731-5. Oncol Rep. 2007. PMID: 17342307

10

Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.

Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Yasuda M, Ochiai K, Tanaka T. Takao M, et al. Among authors: yasuda m. Oncol Rep. 2007 Jun;17(6):1333-9. Oncol Rep. 2007. PMID: 17487387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,560 results

Search Page

Filters